Background: The aim of this study was to investigate whether retinol-binding protein 4 (RBP4) concentrations, measured at the first prenatal visit, are associated with risk of gestational diabetes mellitus (GDM). Methods: From July 2015 to June 2016, consecutive women who admitted to the obstetrics center of our hospital were included. At the first prenatal visit (the median gestational age was 6 [interquartile range 4–10] weeks) in the hospital, involved subjects were tested for fasting plasma glucose (FPG) and RBP4 using venous plasma samples collected after at least 8 h of fasting in the morning. Data for FPG and RBP4 concentrations at the first prenatal visit and one-step GDM screening with 75-g oral glucose tolerance test performed between 24 and 28 weeks of gestation were collected and analyzed. Results: Blood at first prenatal visit was available for 827 women, among whom GDM developed in 101 (12.2%). In multivariate models comparing the second (Q2), third, and fourth quartiles against the first quartile of RBP4, concentrations of RBP4 in Q2, Q3, and Q4 were associated with GDM later developed, and increased risk of GDM by 54, 205, and 536%. There was a significant statistical difference in the area under the curve between the established risk factors alone and the addition of RBP4 concentrations (difference, 0.039 [95% CI 0.030–0.052]; p = 0.03). In the subgroup of women combined with obesity and FABP4 ≥median, the measured OR was 9.83 (95% CI [4.76–16.13]; p < 0.001) for GDM compared to those without obesity and FABP4 <median. Conclusions: There is evidence of a positive association of early pregnancy elevated RBP4 concentration with increased GDM risk, particularly among women with advanced age and obesity.

Keywords:
Retinol-binding protein 4, Gestational diabetes mellitus, Chinese, Association
1.
Abetew DF, Qiu C, Fida NG, Dishi M, Hevner K, Williams MA, et al: Association of retinol binding protein 4 with risk of gestational diabetes. Diabetes Res Clin Pract 2013; 99: 48–53.
2.
Zhu WW, Yang HX, Wang C, Su RN, Feng H, Kapur A: High prevalence of gestational diabetes mellitus in Beijing: effect of maternal birth weight and other risk factors. Chin Med J 2017; 130: 1019–1025.
3.
Tu WJ, Guo M, Shi XD, Cai Y, Liu Q, Fu CW: First-trimester serum fatty acid-binding protein 4 and subsequent gestational diabetes mellitus. Obstet Gynecol 2017; 130: 1011–1016.
4.
Zhang Y, Zhang HH, Lu JH, Zheng SY, Long T, Li YT, et al: Changes in serum adipocyte fatty acid-binding protein in women with gestational diabetes mellitus and normal pregnant women during mid- and late pregnancy. J Diabetes Investig 2016; 7: 797–804.
5.
Quadro L, Blaner WS, Salchow DJ, Vogel S, Piantedosi R, Gouras P, et al: Impaired retinal function and vitamin a availability in mice lacking retinol-binding protein. EMBO J 1999; 18: 4633–4644.
6.
Tamori Y, Sakaue H, Kasuga M: RBP4, an unexpected adipokine. Nat Med 2006; 12: 30–41.
7.
Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552–2563.
8.
Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al: Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006; 29: 2457–2461.
9.
Janke J, Engeli S, Boschmann M, et al: Retinol-binding protein 4 in human obesity. Diabetes 2006; 55: 2805–2810.
10.
Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356–362.
11.
Yao-Borengasser A, Varma V, Bodles AM, Rasouli N, Phanavanh B, Lee MJ, et al: Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 2007; 92: 2590–2597.
12.
Su YX, Hong J, Yan Q, Xu C, Gu WQ, Zhang YF, et al: Increased serum retinol-binding protein-4 levels in pregnant women with and without gestational diabetes mellitus. Diabetes Metab 2010; 36: 470–475.
13.
Lewandowski KC, Stojanovic N, Bienkiewicz M, Tan BK, Prelevic GM, Press M, et al: Elevated concentrations of retinol-binding protein-4 (RBP-4) in gestational diabetes mellitus: negative correlation with soluble vascular cell adhesion molecule-1 (sVCAM-1). Gynecol Endocrinol 2008; 24: 300–305.
14.
Tepper BJ, Kim YK, Shete V, Shabrova E, Quadro L: Serum retinol-binding protein 4 (RBP4) and retinol in a cohort of borderline obese women with and without gestational diabetes. Clin Biochem 2010; 43: 320–323.
15.
Ma H, Yang S, Wang P, Zhang JF: Evaluation of the value of plasma concentration of copeptin in the first prenatal visit to diagnose gestational diabetes mellitus. Acta Diabetol 2017; 54: 1123–1129.
16.
Qiu C, Sorensen TK, Luthy DA, Williams MA: A prospective study of maternal serum C-reactive protein (CRP) concentrations and risk of gestational diabetes mellitus. Paediatr Perinat Epidemiol 2004; 18: 377–384.
17.
Tu WJ, Liu H, Liu Q, Cao JL, Guo M: Association between serum lipoprotein(a) and diabetic retinopathy in Han Chinese patients with type 2 diabetes. J Clin Endocrinol Metab 2017; 102: 2525–2532.
18.
Zhu WW, Yang HX, Wei YM, Yan J, Wang ZL, Li XL, et al: Evaluation of the value of fasting plasma glucose in the first prenatal visit to diagnose gestational diabetes mellitus in China. Diabetes Care 2013; 36: 586–590.
19.
Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172.
20.
Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL: Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998; 22: 39–47.
21.
Hu S, Liu Q, Huang X, Tan H: Serum level and polymorphisms of retinol-binding protein-4 and risk for gestational diabetes mellitus: a meta-analysis. BMC Pregnancy Childbirth 2016; 16: 52.
22.
Du M, Wang B, Liang Z, Dong M, Chen D: The relationship between retinol-binding protein 4 concentrations and gestational diabetes mellitus in Chinese women. Gynecol Obstet Inves 2016; 81: 174–180.
23.
Huang QT, Huang Q, Luo W, Li F, Hang LL, Yu YH: Circulating retinol-binding protein 4 levels in gestational diabetes mellitus: a meta-analysis of observational studies. Gynecol Endocrinol 2015; 31: 337–344.
24.
Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M, et al: Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 2007; 92: 1168–1171.
25.
Sun X, Zhang Z, Ning H, Sun H, Ji X: Sitagliptin down-regulates retinol-binding protein 4 and reduces insulin resistance in gestational diabetes mellitus: a randomized and double-blind trial. Metab Brain Dis 2017; 32: 773–778.
26.
Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, et al: High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 2007; 30: 1173–1178.
27.
Qi Q, Yu Z, Ye X, Zhao F, Huang P, Hu FB, et al: Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab 2007; 92: 4827–4834.
28.
Jia W, Wu H, Bao Y, Wang C, Lu J, Zhu J, et al: Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab 2007; 92: 3224–3229.
29.
Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D: Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab 2007; 92: 1971–1974.
30.
Yang M, Peng S, Li W, Wan Z, Fan L, Du Y: Relationships between plasma leptin levels, leptin G2548A, leptin receptor Gln223Arg polymorphisms and gestational diabetes mellitus in Chinese population. Sci Rep 2016; 6: 23948.
31.
Thagaard IN, Krebs L, Holm JC, Lange T, Larsen T, Christiansen M: Adiponectin and leptin as first trimester markers for gestational diabetes mellitus: a cohort study. Clin Chem Lab Med 2017; 55: 1805–1812.
32.
Tsiotra PC, Halvatsiotis P, Patsouras K, Maratou E, Salamalekis G, Raptis SA, et al: Circulating adipokines and mRNA expression in adipose tissue and the placenta in women with gestational diabetes mellitus. Peptides 2018; 101: 157–166.
33.
Pantham P, Aye IL, Powell TL: Inflammation in maternal obesity and gestational diabetes mellitus. Placenta 2015; 36: 709–715.
34.
Maghbooli Z, Hossein-nezhad A, Mirzaei K, Karimi F, Besharati A, Omidfar K, et al: Association between retinol-binding protein 4 concentrations and gestational diabetes mellitus and risk of developing metabolic syndrome after pregnancy. Reprod Sci 2010; 17: 196–201.
35.
Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Chaiworapongsa T, Kim SK, et al: Retinol-binding protein 4: a novel adipokine implicated in the genesis of LGA in the absence of gestational diabetes mellitus. J Perinat Med 2010; 38: 147–155.
36.
Klein K, Bancher-Todesca D, Leipold H, Knöfler M, Haslinger P, Handisurya A, et al: Retinol-binding protein 4 in patients with gestational diabetes mellitus. J Womens Health 2010; 19: 517–521.
37.
Nanda S, Nikoletakis G, Markova D, Poon LC, Nicolaides KH: Maternal serum retinol-binding protein-4 at 11-13 weeks’ gestation in normal and pathological pregnancies. Metabolism 2013; 62: 814–819.
38.
Khovidhunkit W, Pruksakorn P, Plengpanich W, Tharavanij T: Retinol-binding protein 4 is not associated with insulin resistance in pregnancy. Metabolism 2012; 61: 65–69.
39.
Krzyzanowska K, Zemany L, Krugluger W, Schernthaner GH, Mittermayer F, Schnack C, et al: Serum concentrations of retinol-binding protein 4 in women with and without gestational diabetes. Diabetologia 2008; 51: 1115–1122.
40.
Moraes-Vieira PM, Yore MM, Dwyer PM, Syed I, Aryal P, Kahn BB: RBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistance. Cell Metab 2014; 19: 512–526.
41.
Farjo KM, Farjo RA, Halsey S, Moiseyev G, Ma JX: Retinol-binding protein 4 induces -inflammation in human endothelial cells by an NADPH oxidase- and nuclear factor kappa B-dependent and retinol-independent mechanism. Mol Cell Biol 2012; 32: 5103–5115.
42.
Saucedo R, Valencia J, Basurto L: The retinol binding protein-4 (RBP4) gene and gestational diabetes; Nutrition and Diet in Maternal Diabetes. Cham: Humana Press, 2018, pp 135–145.
43.
Liu G, Ding M, Chiuve SE, Rimm EB, Franks PW, Meigs JB, et al: Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with type 2 diabetes: a 22-year prospective study. Arterioscler Thromb Vasc Biol 2016; 36: 2259–2267.
44.
Huvinen E, Eriksson JG, Stach-Lempinen B, et al: Heterogeneity of gestational diabetes (GDM) and challenges in developing a GDM risk score. Acta Diabetol 2018, Epub ahead of print.
45.
Graham TE, Wason CJ, Blüher M, Kahn BB: Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects. Diabetologia 2007; 50: 814–823.
46.
Von Eynatten M, Lepper PM, Liu D, Lang K, Baumann M, Nawroth PP, et al: Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 2007; 50: 1930–1937.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.